Sage and Biogen receive FDA approval for PPD therapy
Pharmaceutical Business Review
AUGUST 6, 2023
Said to be the first and only oral, once-a-day, 14-day treatment, ZURZUVAE can provide quick improvements in depressive symptoms for women with PPD. Shortly after scheduling as a controlled substance by the US Drug Enforcement Administration, the therapy is anticipated to be launched and will be commercially available in the fourth quarter of this year.
Let's personalize your content